GODIF Newsletter December to February 2023

Thank you for committing to the GODIF trial!

Dear friends and colleagues,

A warm welcome to the ICUs in Reykjavik (IS), Tampere (F), Gødstrup (DK), and Aarhus (DK) who are expected to start inclusion of patients in March 2023. We are happy to have you on board and we appreciate the collaboration.

The next sites expected to start the GODIF trial are the ICUs in Randers (DK) and Viborg (DK). We will soon be 20-21 active sites in the team. Several countries are still in the application process of getting GODIF approved.

The recruitment is as follows the 20.02.2023:



90-day follow-up

When entering data for the 90-day follow-up, additional admissions to a hospital must be reported. Outpatient visits to the hospital or assessments in the emergency department not resulting in admission to the hospital should not be registered as admissions.

New documents for your site master file.

- Annual safety report for 2022
- Trial synopsis updated (minor adjustments)
- An Updated EudraCT (for the Danish sites only)

New documents will always be attached to the newsletter sent out four times a year.

1-year follow-up

1-year follow-up is going well. The new MoCA-mini is slightly different from the former versions. Instructions can be found on the homepage. If none of your research staff members involved in the GODIF trial has a MoCA certificate, please get in touch with the coordinating centre when the time is near for you to start the 1-year follow-up.

The GODIF trial first version is published

In August 2020 we launched the GODIF trial for the first time. In this first version of the GODIF trial, the cumulative fluid balance was used as the parameter for fluid overload and neutral fluid balance. We stopped the trial after 6 months and 41 included patients, as it became clear that the cumulative fluid balance as the only parameter to describe fluid overload and neutral fluid balance was too inaccurate in about one-third of the patients. The results for the 90-day outcomes for the 41 participants are now published:

Goal-directed fluid removal with furosemide versus placebo in intensive care patients with fluid overload: A randomised, blinded trial (GODIF trial—First version). Sine Wichmann, Martin Schønemann-Lund, Anders Perner, Theis S. Itenov, Theis Lange, Christian Gluud, Rasmus E. Berthelsen, Anne C. Brøchner, Jørgen Wiis, Morten H. Bestle.

First published: 12 January 2023 https://doi.org/10.1111/aas.14196

The Coordinating Center is always available on the
GODIF hotline: +45 48 29 67 73
Mail: godif@cric.nu
www.cric.nu/godif/
Kind Regards form the GODIF team
Morten (Sponsor) and Sine (Coordinating Investigator)

All the best,

Morten and Sine